Eli Lilly: Clinical trial of COVID-19 antibody treatment paused for safety concern
|Eli Lilly and Company, an American pharmaceutical company headquartered in Indianapolis, announced on Tuesday that it paused the clinical trial of its COVID-19 antibody treatment due to safety concerns, as reported by Reuters.
"Independent Data Safety Monitoring Board recommended a pause in enrollment in Activ-3 trial of COVID antibody treatment," the company explained.
Market reaction
The company's shares (LLY: NYSE) fell sharply with the initial reaction and were last seen losing 3% on the day at $149.87. Moreover, this headline seems to be weighing on market sentiment. As of writing, the S&P 500 Index was down 0.8% on the day at 3,506.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.